BioMed Research International / 2019 / Article / Tab 2 / Review Article
Safety and Efficacy in Relapsed or Refractory Classic Hodgkin’s Lymphoma Treated with PD-1 Inhibitors: A Meta-Analysis of 9 Prospective Clinical Trials Table 2 The pooled AEs incidence in all-grade or grade ≥3 or individual.
AEs Data points No. Event rate 95% CI Heterogeneity I 2 (%)I 2 All-grade 9 681 0.86 0.66–0.98 97.0 <0.01 Grade ≥ 3 8 471 0.21 0.17–0.24 69.0 <0.01 Individual AEs General disorders Asthenia 2 241 0.03 0.01–0.06 64.0 0.09 Back pain 3 470 0.07 0.02–0.22 85.0 <0.01 Blurred vision 2 27 0.15 0.06–0.34 0.0 0.56 Fatigue 7 615 0.18 0.09–0.31 89.0 <0.01 Infusion-related reactions (IRRs) 4 417 0.17 0.07–0.36 91.0 <0.01 Nasopharyngitis 3 470 0.08 0.01–0.34 90.0 <0.01 Oropharyngeal pain 2 453 0.10 0.08–0.13 57.0 0.13 Pyrexia 6 650 0.28 0.22–0.36 66.0 0.01 Upper respiratory tract infection 5 576 0.07 0.02–0.22 89.0 <0.01 Gastrointestinal disorders Abdominal pain 2 304 0.14 0.11–0.19 0.0 0.94 Constipation 5 562 0.08 0.04–0.16 74.0 <0.01 Diarrhea 8 691 0.15 0.08–0.28 88.0 <0.01 Nausea 6 598 0.18 0.09–0.33 90.0 <0.01 Vomiting 4 545 0.11 0.05–0.24 88.0 <0.01 Skin disorders Myalgia 5 541 0.10 0.05–0.18 74.0 <0.01 Nasal congestion 3 514 0.08 0.03–0.21 89.0 <0.01 Rash 8 690 0.18 0.13–0.25 69.0 <0.01 Pruritus 6 564 0.17 0.09–0.31 85.0 <0.01 Hepatic disorders ALT level increased 2 274 0.08 0.05–0.11 0.0 0.79 AST level increased 2 274 0.07 0.05–0.11 0.0 0.85 Hepatic function abnormal 2 113 0.05 0.02–0.12 55.0 0.14 Lipase level increased 2 119 0.07 0.03–0.13 0.0 0.68 Thyroid disorders Hypothyroidism 5 410 0.16 0.09–0.26 72.0 <0.01 Thyroiditis 2 274 0.02 0.00–0.16 77.0 0.04 Musculoskeletal disorders Arthralgia 3 514 0.10 0.04–0.24 89.0 <0.01 Respiratory disorders Chills 3 302 0.07 0.02–0.23 85.0 <0.01 Cough 4 537 0.15 0.05–0.36 94.0 <0.01 Dyspnea 5 555 0.09 0.04–0.19 80.0 <0.01 Pneumonia 4 380 0.11 0.08–0.15 0.0 0.99 Nervous system disorders Dizziness 2 78 0.13 0.07–0.22 0.0 0.88 Headache 3 321 0.20 0.16–0.25 0.0 0.58 Peripheral sensory neuropathy 2 71 0.32 0.05–0.80 88.0 <0.01 Blood and lymphatic system disorders Alanine aminotransferase increased 3 349 0.14 0.03–0.45 92.0 <0.01 Alkaline phosphatase increased 4 380 0.06 0.04–0.09 31.0 0.22 Anemia 2 306 0.09 0.06–0.12 0.0 0.61 Aspartate aminotransferase increased 3 349 0.09 0.02–0.37 90.0 <0.01 Decreased lymphocyte count 5 701 0.05 0.04–0.07 0.0 0.72 Decreased platelet count 2 119 0.13 0.08–0.20 0.0 0.44
